CFDE Data Portal | Search ACAD9-DT

	Label	Description
	ACAD9-DT Gene (Entity type)	ENSG00000287110 - ACAD9 divergent transcript
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193351 ruxolitinib 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE129542 BAT1 knockdown RNA Small Interfering 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE173116 GSE173118 ML-7 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE196343 metformin 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE241036 0 V 1 ETHANOL MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE212312 FBXW7 knockout Reh 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE183535 MYC inhibition HeLa 0 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS

ACAD9-DT

ENSG00000287110 - ACAD9 divergent transcript

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE193351 ruxolitinib 1 v 2 human dn

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE129542 BAT1 knockdown RNA Small Interfering 0 v 2 human up

A Gene Set from LINCS

GSE173116 GSE173118 ML-7 3 v 5 human up

A Gene Set from LINCS

GSE196343 metformin 1 v 0 human dn

A Gene Set from LINCS

GSE241036 0 V 1 ETHANOL MOUSE DN

A Gene Set from LINCS

GSE212312 FBXW7 knockout Reh 1 v 3 human up

A Gene Set from LINCS

GSE183535 MYC inhibition HeLa 0 v 6 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.